Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Massimo Donadelli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9224-9230; OpenAlex author ID A5058548647. Sources: OpenAlex.

Their work

Papers
29 (first author 2, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 6 papers · 2014: 1 paper · 2015: 3 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: 3 papers · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 4 papers

Papers 29

  1. First-in-Class Covalent Inhibitors of PFKFB3: Discovery and Characterization in PDAC Models. Co-author DOI 10.1021/acs.jmedchem.6c00235↗
  2. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Co-author DOI 10.1097/sla.0000000000006565↗
  3. Mutant p53 affects the mitochondrial proteome, promoting mitochondrial fragmentation and OXPHOS in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1111/febs.70223↗
  4. Metabolic plasticity underlies ferroptosis resistance driven by mutant p53 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-026-02746-y↗
  5. Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. Last author DOI 10.1038/s41419-025-08082-1↗
  6. Simulated Microgravity-Induced Alterations in PDAC Cells: A Potential Role for Trichostatin A in Restoring Cellular Phenotype. Co-author DOI 10.3390/ijms26104758↗
  7. Discovery of a spirocyclic 3-bromo-4,5-dihydroisoxazole covalent inhibitor of hGAPDH with antiproliferative activity against pancreatic cancer cells. Co-author DOI 10.1016/j.ejmech.2023.115286↗
  8. Prolonged exposure to simulated microgravity promotes stemness impairing morphological, metabolic and migratory profile of pancreatic cancer cells: a comprehen… Co-author DOI 10.1007/s00018-022-04243-z↗
  9. Tumor Suppressor Role of Wild-Type P53-Dependent Secretome and Its Proteomic Identification in PDAC. Last author DOI 10.3390/biom12020305↗
  10. 3-Bromo-Isoxazoline Derivatives Inhibit GAPDH Enzyme in PDAC Cells Triggering Autophagy and Apoptotic Cell Death. Last author DOI 10.3390/cancers14133153↗
  11. MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells. Last author DOI 10.1016/j.bbamcr.2020.118824↗
  12. The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells. Last author DOI 10.3390/biom10060884↗
  13. Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine. Co-author DOI 10.3390/ijms22010029↗
  14. Trichostatin A alters cytoskeleton and energy metabolism of pancreatic adenocarcinoma cells: An in depth proteomic study. Last author DOI 10.1002/jcb.26436↗
  15. Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity. Last author DOI 10.1016/j.bbamcr.2018.10.005↗
  16. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Last author DOI 10.1016/j.bbamcr.2014.10.003↗
  17. Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt/mTOR pathway in a ROS-dependent manner. Last author DOI 10.1016/j.bbamcr.2014.12.016↗
  18. Mitochondrial uncoupling protein 2 and pancreatic cancer: a new potential target therapy. Co-author DOI 10.3748/wjg.v21.i11.3232↗
  19. Bovine seminal ribonuclease triggers Beclin1-mediated autophagic cell death in pancreatic cancer cells. Last author DOI 10.1016/j.bbamcr.2014.01.025↗
  20. Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists. Co-author DOI 10.1002/elps.201200402↗
  21. Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. Last author DOI 10.1007/s10495-012-0790-6↗
  22. UCP2 inhibition triggers ROS-dependent nuclear translocation of GAPDH and autophagic cell death in pancreatic adenocarcinoma cells. Last author DOI 10.1016/j.bbamcr.2012.10.028↗
  23. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Co-author DOI 10.1016/j.bbamem.2013.01.020↗
  24. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. First author DOI 10.1038/cddis.2013.151↗
  25. Roles for microRNA 23b in regulating autophagy and development of pancreatic adenocarcinoma. Co-author DOI 10.1053/j.gastro.2013.09.037↗
  26. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Co-author DOI 10.1016/j.ajpath.2012.07.016↗
  27. Proteomics in pancreatic cancer research. Last author DOI 10.1002/pmic.201000401↗
  28. Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives. First author DOI 10.1016/j.freeradbiomed.2011.01.001↗
  29. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Co-author DOI 10.1038/cddis.2011.36↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Raffaella Pacchiana · 10 shared papers, 2018–2026 · strength 1.67
  2. Adriana Celesia · 4 shared papers, 2025–2026 · strength 0.95
  3. Alessandra Fiore · 4 shared papers, 2025–2026 · strength 0.95
  4. Daniela Cecconi · 7 shared papers, 2011–2026 · strength 0.89
  5. Federica Danzi · 3 shared papers, 2025–2026 · strength 0.72
  6. Claudio Luchini · 3 shared papers, 2025–2026 · strength 0.68
  7. Emílio Marengo · 5 shared papers, 2018–2025 · strength 0.68
  8. Aldo Scarpa · 7 shared papers, 2011–2026 · strength 0.64
  9. Paola Conti · 4 shared papers, 2018–2026 · strength 0.63
  10. Elisa Dalla Pozza · 11 shared papers, 2011–2022 · strength 0.61
  11. Ilaria Dando · 11 shared papers, 2011–2022 · strength 0.57
  12. Jessica Brandi · 5 shared papers, 2013–2025 · strength 0.56
  13. Marta Palmieri · 12 shared papers, 2011–2020 · strength 0.56
  14. Maria Poles · 2 shared papers, 2026 · strength 0.53
  15. Giovanna Butera · 4 shared papers, 2018–2025 · strength 0.52
  16. Antonio Pea · 2 shared papers, 2025–2026 · strength 0.43
  17. Roberto Salvia · 2 shared papers, 2025–2026 · strength 0.43
  18. Chiara Borsari · 2 shared papers, 2023–2026 · strength 0.41
  19. Maria Angela Masini · 2 shared papers, 2022–2025 · strength 0.35
  20. Silvia Arpicco · 4 shared papers, 2011–2020 · strength 0.27
  21. Claudia Fiorini · 5 shared papers, 2013–2015 · strength 0.26
  22. Francesca Masetto · 2 shared papers, 2020–2022 · strength 0.24
  23. Matteo De Pastena · 1 shared paper, 2026 · strength 0.24
  24. Giuseppe Malleo · 1 shared paper, 2026 · strength 0.24
  25. Matteo Fassan · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.